The effectiveness of antidepressants and psychological interventions in treating conversion disorder, motor type: a randomized placebo controlled clinical trial.

Phase 3

Completed

Conditions: hysteria
unexplained medical symptoms
10077546

Registration Number: NL-OMON33963

Lead Sponsor: GGZ Nijmegen (Nijmegen)

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 105

Inclusion Criteria

1) Current DSM-IV disorder of Conversion Disorder motor type as established with a structured diagnostic interview (MINI)
2) Age minimum of 18 years
3) Duration of symptoms at least one month
4) Exclusive neurological examinations must have taken place (e.g. MRI, EMG, etc.) in which no neurological or other somatic explanation for the symptoms is found.

Exclusion Criteria

1) A neurological disorder that can fully explain the symptoms as concluded by neurological examination (MRI, EMG, etc.)*
2) Psychosis or delusion disorder (current or in the past)
3) Suicidality
4) Mental retardation
5) Substance abuse or dependence
6) Hypersensitivity to citalopram
7)The use of citalopram currently or in the past when described in an adequate dosage to treat conversion symptoms
8)The use of another SSRI (currently)
9) Reduced hepatic or renal function
10) Pregnancy and lactation
11)The use of a drug which has known negative interaction effects with citalopram:
a) MAO inhibiters (currently or recent)
b) pimozide
12) Difficulty to understand the Dutch language.
* A concomitant neurological disorder is no exclusion criteria when symptoms are not fully explained by the condition and criteria for conversion disorder are met.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameters are improvement in intensity of conversion symptoms<br /><br>as measured with the VRMC (Moene et al. 2002), the number of conversion<br /><br>symptoms as measured with the SCID I and improvement on the Clinical Global<br /><br>Improvement Scale. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secundary outcome measurues will be general psychopathology measures, f.i.<br /><br>depression, anxiety and physical complaints and daily life functioning. </p><br>